OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 0.930
- -0.065-6.54%
Close Mar 31 16:00 ET
21.60MMarket Cap-1.22P/E (TTM)
0.986High0.894Low194.16KVolume0.965Open0.995Pre Close180.98KTurnover1.71%Turnover RatioLossP/E (Static)23.23MShares1.92952wk High-7.69P/B10.57MFloat Cap0.51252wk Low--Dividend TTM11.37MShs Float8.180Historical High--Div YieldTTM9.22%Amplitude0.400Historical Low0.932Avg Price1Lot Size
NeuroSense Therapeutics Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
31
14
2
$NeuroSense Therapeutics (NRSN.US)$
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
Monday, 17th March at 8:30 am
NeuroSense's Breakthrough ALS Combination Therapy PrimeC Has Demonstrated Unprecedentedly Strong Clinical Efficacy; Wall Street Maintains Buy Rating with AGP giving the company a $7.50 Price Target Representing a Significant Premium Over Current Prices; Recently Announced Bindin...
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
Monday, 17th March at 8:30 am
NeuroSense's Breakthrough ALS Combination Therapy PrimeC Has Demonstrated Unprecedentedly Strong Clinical Efficacy; Wall Street Maintains Buy Rating with AGP giving the company a $7.50 Price Target Representing a Significant Premium Over Current Prices; Recently Announced Bindin...
3
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, ...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, ...
68
25
13
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
Monday, 6th January at 9:00 am
• NeuroSense in Compliance with all Nasdaq Listing Requirements
CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from The Nas...
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
Monday, 6th January at 9:00 am
• NeuroSense in Compliance with all Nasdaq Listing Requirements
CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from The Nas...
1
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
Monday, 23rd December at 9:00 am
• Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study
• Additionally, milestone payments and double-digit royalties on annual net sales
• The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025
CAMBRIDGE, Mass., Dec. 23, 2024 /...
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
Monday, 23rd December at 9:00 am
• Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study
• Additionally, milestone payments and double-digit royalties on annual net sales
• The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025
CAMBRIDGE, Mass., Dec. 23, 2024 /...
1
$NeuroSense Therapeutics (NRSN.US)$ Finally but seems to be fitting a pattern lately! PR then a day to a week later, then moves! Hehehe![]()
$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Therapeutics: Initiated the Regulatory Process to Seek Early Commercialization Approval for PrimeC Under Health Canada >NRSN
Dow Jones· 7 mins ago
Dow Jones· 7 mins ago
$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
Wednesday, 11th December at 9:25 am
• The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025
• PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS
CAMBRIDGE, Mass., Dec. 11, 2024 /PRNe...
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
Wednesday, 11th December at 9:25 am
• The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025
• PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS
CAMBRIDGE, Mass., Dec. 11, 2024 /PRNe...
$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Announces PARADIGM Study Results Showing PrimeC Slows ALS Progression By 33% And Improves Survival By 58%, Redefining Potential Standard Of Care In ALS Treatment
Benzinga· 4 mins ago
Benzinga· 4 mins ago
No comment yet
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Mangkawat : dr jag. delution of pnbk.us mean possible to decline?
Jaguar8 OP Mangkawat : The news itself is dilution for existing shareholders BUT take note not all PP plummets. It all comes down to market sentiment. Look at it- it is up.
HannChau : bro just rest you don't owe anyone anything here.
Riyan5426 : take care
别关注我 你们很烦 : $Phoenix Motor (PEV.US)$ Should this Stocks be exited?
View more comments...